Vaximm

Vaximm is dedicated to developing active immunotherapies in the form of oral T-cell vaccines for cancer patients. The company's lead product candidate, VXM01, targets the tumor vasculature, which is crucial for tumor growth. Vaximm's innovative approach utilizes modified attenuated bacteria to create first-in-class oral T-cell activators that can be adapted to target various cancer-related antigens. This technology aims to provide effective treatment options that enhance recovery for patients suffering from cancer. The company has demonstrated significant anti-tumor activity in animal studies and is preparing to enter human clinical trials.